Severe Toxicities In Lymphoma

DelveInsight’s ‘Severe Toxicities in Lymphoma - Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the Severe Toxicities in Lymphoma, historical and forecasted epidemiology as well as the Severe Toxicities in Lymphoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.


The Severe Toxicities in Lymphoma market report provides current treatment practices, emerging drugs, Severe Toxicities in Lymphoma market share of the individual therapies, current and forecasted Severe Toxicities in Lymphoma market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Severe Toxicities in Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2018–2030

Severe Toxicities in Lymphoma Disease Understanding and Treatment Algorithm

Severe Toxicities in Lymphoma Overview

Lymphoma is a broad term used for cancer that begins in infection-fighting cells of the immune system, called lymphocytes. Lymph nodes act as filters, capturing and destroying bacteria and viruses to prevent infection from spreading. Lymphocytes travel through the blood and lymphatic system to defend the body against foreign invaders like bacteria and viruses. Lymphoma can be categorized into two main types, which are called, Hodgkin lymphoma and Non-Hodgkin lymphoma. Hodgkin lymphoma contains cells called Reed Sternberg cells. Reed Sternberg cells are a type of white blood cell called a B lymphocyte that has become cancerous. Non-Hodgkin lymphoma is the most common form of lymphoma. It tends to develop in older adults. While it can occur at any age, most people who develop the illness are older adults.


Current therapeutic options for Lymphoma include Chemotherapy, Radiation Therapy, and some Targeted Therapies, such as antibody treatment, CAR-T cell therapy, etc. People who have been treated for lymphoma are more at risk of developing certain health problems in later life. Despite high rates of response, lymphoma survivors have increased morbidity and mortality compared to the general population because of long-term therapy-related events. Late complications of treatment include cardiovascular diseases, lung diseases, endocrine abnormalities, and secondary malignancies. Second malignancies followed by cardiovascular disease are the leading causes of late morbidity and mortality. Also, musculoskeletal difficulties, endocrine abnormalities including sterility and thyroid disease, heart and lung damage, persistent fatigue, and psychosocial distress have been seen.


Chemotherapy, the cornerstone of treatment, is associated with considerable toxicity, especially bone marrow suppression, which calls for transfusion support and infection prophylaxis. Toxicity related to the oral-gastrointestinal tract such as nausea and vomiting, as well as mucositis, are also common. The frequency and severity of toxicities are more pronounced in the case of relapsed or refractory lymphoma where the standard of care is high-dose therapy (HDT) and autologous stem cell transplantation (ASCT).


Findings from the secondary domain suggest that older patients with lymphoma experience greater toxicity in comparison to their younger counterparts, yet they would derive similar benefit from standard chemotherapy. Different toxicities may result in various types of diseases.


Severe Toxicities in Lymphoma Diagnosis

Restaging procedures are done at the end of chemotherapy and after the completion of adjuvant radiotherapy. These procedures include complete blood count, biochemistry, and lung and abdomen computed tomography imaging. Nuclear magnetic resonance is used only in special circumstances. All patients are regularly followed up every 3 months for the first 2 years after complete response, and annually thereafter. Thoracic and abdominal computerized tomography is done every 6 months for the first 2 years of follow-up, and then at the treating physician’s discretion.


Organ-specific monitoring is performed during the treatment of lymphoma to detect any severe toxicities. For example, pulmonary function tests including spirometric evaluation of forced vital capacity and forced expiratory volume, measurement of single-breath carbon monoxide diffusing capacity, and arterial blood gas determination are done in all patients with respiratory symptoms during or after the end of therapy. Cardiac function is evaluated by two-dimensional echography and measurement of left ventricular ejection fraction; a thorough cardiac evaluation is carried out in the presence of cardiac symptoms. Thyroid hormones are tested every 6 months for the first 5 years after the end of therapy. In women, the gonadal function is assessed by menses evaluation and by testing plasma level of estradiol, progesterone, and prolactin before and after therapy.


Severe Toxicities in Lymphoma Treatment

Current treatment options available for the severe toxicities in lymphoma remain very scarce. To reduce toxicities associated with lymphoma, medical practitioners also try to reduce the dosing or number of cycles of chemotherapy. Also, significant follow-up care is also used to have an early detection of any toxicity showing in the patients to be prepared for the toxicities. Therefore, even if there is availability of drugs to treat lymphoma but still large patient population is facing the unmet need of effective treatment option which will not cause the toxicities or drugs which can show benefit in treating the toxicities due to HDT.

Severe Toxicities in Lymphoma Epidemiology

The Severe Toxicities in Lymphoma epidemiology division provides the insights about historical and current Severe Toxicities in Lymphoma patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Severe Toxicities in Lymphoma epidemiology segmented as Total Incident Cases of lymphoma,


Type-specific Incident cases of Lymphoma, Stage-Specific Incidence of Lymphoma, Chemotherapy Treated Lymphoma Patients, and Frequency of Severe Toxicities in Lymphoma Patients] scenario of Severe Toxicities in Lymphoma in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Country Wise- Severe Toxicities in Lymphoma Epidemiology

  • For 2020, 198,600 incident cases of Lymphoma were estimated in the 7MM. The United States, in 2020, accounted for nearly 41% of the total 7MM cases. Among the EU-5 countries, the highest number of cases of Lymphoma accessed for Germany, i.e. 20,855 cases in 2020, which are estimated to rise by the year 2030. Furthermore, Japan accounted for about 17% of the total 7MM incident cases of Lymphoma in 2020.  
  • In the 7MM, among the stage-specific Lymphoma patients, a high number of patients were estimated to be in early-stage, i.e., Stage I (73,482). This was followed by Stage IV (65,538). Contrary to this, Stage III (31,776) and Stage II (27,804) accounted for comparatively less percentage in 2020.
  • In the 7MM, 160,370 naïve lymphoma patients, and 63,506 relapsed/refractory lymphoma patients were estimated to be treated with chemotherapy in 2020.
  • In the 7MM, 16,037 naïve patients were estimated to suffer from severe toxicities. For the Relapsed/Refractory pool, the cases were estimated to be around 36,199 in 2020.
  • In 2020, 2,804 naïve patients, and 6,329 relapsed/refractory cases were estimated with severe toxicities in Japan.

Severe Toxicities in Lymphoma Drug Chapters

Drug chapter segment of the Severe Toxicities in Lymphoma report encloses the detailed analysis of Severe Toxicities in Lymphoma developmental stage pipeline drugs. It also helps to understand the Severe Toxicities in Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Severe Toxicities in Lymphoma Emerging Drugs


AB-205: Angiocrine Bioscience

AB-205 is a novel, experimental, cellular therapy by Angiocrine Bioscience intended for treatment of toxicities related to high-dose chemotherapy with or without radiation. The company is currently conducting a phase I (NCT03925935) first-in-human, open-label, non-randomized, safety study of AB-205-001 (ongoing) in patients with relapsed, chemo-sensitive, non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who are undergoing high-dose therapy (HDT) and autologous stem cell transplantation (ASCT).

Note: Detailed emerging therapies assessment will be provided in the final report.

Severe Toxicities in Lymphoma Market Outlook

Key Findings

The Severe Toxicities in Lymphoma market size in the 7MM is expected to rise at a CAGR of 9.3%, during the study period 2018–2030. The highest market size of Severe Toxicities in Lymphoma is estimated for the United States followed by Japan, Germany, and the UK.


The United States Market Outlook

The Severe Toxicities in Lymphoma market size in the United States is expected to rise at a CAGR of 10.2%, during the study period 2018–2030.


EU-5 Countries: Market Outlook

The Severe Toxicities in Lymphoma market size in the 7MM is expected to rise at a CAGR of 8.0%, during the study period 2018–2030.


Japan Market Outlook

The Severe Toxicities in Lymphoma market size in the 7MM is expected to rise at a CAGR of 7.7%, during the study period 2018–2030.

Severe Toxicities in Lymphoma Pipeline Development Activities

The drugs which are in pipeline include:


  • AB-205: Angiocrine Bioscience

Note: Detailed emerging therapies assessment will be provided in the final report.

Severe Toxicities in Lymphoma Drugs Uptake

Analysts Insight


AB-205 (Angiocrine Biosciences) is being investigated in phase I/II in adults with lymphoma undergoing high-dose therapy and autologous stem cell transplantation. The company has recently presented promising results from the phase Ib/II study and is actively planning to advance AB-205 into a multi-center single registration Phase III trial. It is projected that this candidate is likely to enjoy a monopoly, as there is no visibility on other competitors in this space as of now.

Access and Reimbursement Scenario in Severe Toxicities in Lymphoma Therapies

For severe toxicities related to high-dose therapy and autologous stem cell transplantation in lymphoma patients, no therapy has been approved by the regulatory authorities. Hence, it is too soon to predict the access and reimbursement scenario of emerging therapies. However, it is worth mentioning that if the emerging candidates for severe toxicities in lymphoma show promising and superior safety and efficacy profile then the chances to get thumbs up from health technology assessment (HTA) bodies will be somewhat easier task for investigators. It is important to mention that the pricing policy of any drug considers remuneration of research, manufacturing, and marketing costs, as well as a good return for investors. The high prices combined with comparatively insufficient clinical data may lead to substantial complications for market access, as the economic burden on lymphoma patients is already high.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Severe Toxicities in Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Severe Toxicities in Lymphoma Severe Toxicities in Lymphoma market trend. This will support the clients in potential upcoming novel treatment by identifying the over Severe Toxicities in Lymphoma scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Severe Toxicities in Lymphoma Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Severe Toxicities in Lymphoma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Severe Toxicities in Lymphoma epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Severe Toxicities in Lymphoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Severe Toxicities in Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Severe Toxicities in Lymphoma market.

Report Highlights

  • In the coming years, Severe Toxicities in Lymphoma market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Severe Toxicities in Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Severe Toxicities in Lymphoma. Launch of emerging therapies, will significantly impact the Severe Toxicities in Lymphoma market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Severe Toxicities in Lymphoma.
  • Our in-depth analysis of the pipeline assets across different stages of development different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the over Severe Toxicities in Lymphoma scenario of the research and development activities.

Severe Toxicities in Lymphoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Severe Toxicities in Lymphoma Pipeline Analysis
  • Severe Toxicities in Lymphoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Severe Toxicities in Lymphoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Severe Toxicities in Lymphoma Epidemiology Segmentation
  • Highly Analyzed Market
  • Drugs Uptake

Severe Toxicities in Lymphoma Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Severe Toxicities in Lymphoma Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Severe Toxicities in Lymphoma total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Severe Toxicities in Lymphoma market size during the study period (2018–2030)?
  • At what CAGR, the Severe Toxicities in Lymphoma market is expected to grow in the 7MM during the study period (2018–2030)?
  • What would be the Severe Toxicities in Lymphoma market outlook across the 7MM during the study period (2018–2030)?
  • What would be the Severe Toxicities in Lymphoma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Severe Toxicities in Lymphoma patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Severe Toxicities in Lymphoma market?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Severe Toxicities in Lymphoma?
  • What is the historical Severe Toxicities in Lymphoma patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Severe Toxicities in Lymphoma in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Severe Toxicities in Lymphoma?
  • Out of Severe Toxicities in Lymphoma the 7MM countries, which country would have the highest incident population of Severe Toxicities in Lymphoma during the study period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Severe Toxicities in Lymphoma?


Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Severe Toxicities in Lymphoma?
  • What are the current treatment guidelines for the treatment of Severe Toxicities in Lymphoma in the US, Europe and Japan?
  • How many companies are developing therapies for the treatment of Severe Toxicities in Lymphoma?
  • How many therapies are developed by each company for the treatment of Severe Toxicities in Lymphoma?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Severe Toxicities in Lymphoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Toxicities in Lymphoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Severe Toxicities in Lymphoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Severe Toxicities in Lymphoma?
  • What is the global historical and forecasted market of Severe Toxicities in Lymphoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Severe Toxicities in Lymphoma market.
  • To understand the future market competition in the Severe Toxicities in Lymphoma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Severe Toxicities in Lymphoma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Severe Toxicities in Lymphoma market.
  • To understand the future market competition in the Severe Toxicities in Lymphoma market.

1. Key Insights

2. Executive Summary of Severe Toxicities in Lymphoma

3. SWOT Analysis

4. Severe Toxicities in Lymphoma Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Severe Toxicities in Lymphoma: Disease Background and Overview

6.1. Introduction

6.2. Staging of Lymphoma

6.3. Current therapeutic options for lymphoma

6.3.1. Chemotherapy

6.3.2. Targeted Therapies

6.3.3. Radiation Therapy

6.4. Severe Toxicities due to Lymphoma treatment

6.4.1. Cardiovascular Diseases

6.4.2. Pulmonary Diseases

6.4.3. Hormone problems

6.4.4. Second cancer

6.4.5. CAR T-cell toxicities

6.4.6. Other late effects

6.5. Risk factors for toxicities in lymphoma

6.6. Diagnosis

6.6.1. Tests for Lung disorders due to toxicities

6.6.2. Tests for thyroid abnormalities due to toxicities

6.6.3. Tests for fertility in females

6.6.4. Tests for Cardiovascular disorders due to toxicities

6.6.5. Tests for Second Cancers due to toxicities

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. 7MM Epidemiology

7.3.1. Total Incident Cases of lymphoma in the 7MM

7.3.2. Type-specific Incident cases of Lymphoma in 7MM

7.3.3. Stage-Specific Incidence of Lymphoma in the 7MM

7.3.4. Chemotherapy Treated Lymphoma Patients in the 7MM

7.3.5. Frequency of Severe Toxicities in Lymphoma Patients in the 7MM

7.4. The United States Epidemiology

7.4.1. `Total Incident cases of Lymphoma in the United States

7.4.2. Type-specific Incident cases of Lymphoma in the United States

7.4.3. Stage-Specific Incidence of Lymphoma in the United States

7.4.4. Chemotherapy Treated Lymphoma Patients in the United States

7.4.5. Frequency of Severe Toxicities in Lymphoma Patients in the United States

7.5. EU-5 Epidemiology

7.6. Germany

7.6.1. Total Incident cases of Lymphoma in Germany

7.6.2. Type-specific Incident cases of Lymphoma in Germany

7.6.3. Stage-Specific Incidence of Lymphoma in Germany

7.6.4. Chemotherapy Treated Lymphoma Patients in Germany

7.6.5. Frequency of Severe Toxicities in Lymphoma Patients in Germany

7.7. France

7.7.1. Total Incident cases of Lymphoma in France

7.7.2. Type-specific Incident cases of Lymphoma in France

7.7.3. Stage-Specific Incidence of Lymphoma in France

7.7.4. Chemotherapy Treated Lymphoma Patients in France

7.7.5. Frequency of Severe Toxicities in Lymphoma Patients in France

7.8. Italy

7.8.1. Total Incident cases of Lymphoma in Italy

7.8.2. Type-specific Incident cases of Lymphoma in Italy

7.8.3. Stage-Specific Incidence of Lymphoma in Italy

7.8.4. Chemotherapy Treated Lymphoma Patients in Italy

7.8.5. Frequency of Severe Toxicities in Lymphoma Patients in Italy

7.9. Spain

7.9.1. Total Incident cases of Lymphoma in Spain

7.9.2. Type-specific Incident cases of Lymphoma in Spain

7.9.3. Stage-Specific Incidence of Lymphoma in Spain

7.9.4. Chemotherapy Treated Lymphoma Patients in Spain

7.9.5. Frequency of Severe Toxicities in Lymphoma Patients in Spain

7.10. The United Kingdom

7.10.1. Total Incident cases of Lymphoma in the United Kingdom

7.10.2. Type-specific Incident cases of Lymphoma in the United Kingdom

7.10.3. Stage-Specific Incidence of Lymphoma in the United Kingdom

7.10.4. Chemotherapy Treated Lymphoma Patients in the United Kingdom

7.10.5. Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom

7.11. Japan Epidemiology

7.11.1. Total Incident cases of Lymphoma in Japan

7.11.2. Type-specific Incident cases of Lymphoma in Japan

7.11.3. Stage-Specific Incidence of Lymphoma in Japan

7.11.4. Chemotherapy Treated Lymphoma Patients in Japan

7.11.5. Frequency of Severe Toxicities in Lymphoma Patients in Japan

8. Current Treatment Practices: Severe Toxicities in Lymphoma

8.1. Cardiovascular Disease

8.2. Lung Disease

8.3. Thyroid Abnormalities

8.4. Female Fertility

9. Unmet Needs

10. Patient Journey 

11. Key Endpoints in Severe Toxicities in Lymphoma Clinical Trials

12. Emerging Therapies

12.1. AB-205: Angiocrine Bioscience

12.1.1. Product Description

12.1.2. Other Developmental Activities

12.1.3. Clinical Development

12.1.4. Safety and Efficacy

13. Severe Toxicities in Lymphoma Seven Major Market Analysis

13.1. Key Finding

13.2. 7MM Market Size

13.2.1. Total Market Size of Severe Toxicities in Lymphoma in the 7MM

13.2.2. Total Market size of Severe Toxicities in Lymphoma by Therapies in the 7MM

13.3. The United States Market Size

13.3.1. Total Market size of Severe Toxicities in Lymphoma in the United States

13.4. EU-5 Market Size

13.5. Germany Market Size

13.5.1. Total Market size of Severe Toxicities in Lymphoma in Germany

13.6. France Market Size

13.6.1. Total Market size of Severe Toxicities in Lymphoma in France

13.7. Italy Market Size

13.7.1. Total Market size of Severe Toxicities in Lymphoma in Italy

13.8. Spain Market Size

13.8.1. Total Market size of Severe Toxicities in Lymphoma in Spain

13.9. The United Kingdom Market Size

13.9.1. Total Market size of Severe Toxicities in Lymphoma in the United Kingdom

13.10. Japan Market Size

13.10.1. Total Market size of Severe Toxicities in Lymphoma in Japan

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Severe Toxicities in Lymphoma Market, Epidemiology, and Key Events (2018–2030)

Table 2: Type of B-cell Lymphoma

Table 3: Type of T cell Lymphoma

Table 4: Chemotherapy drugs for Non-Hodgkin Lymphoma

Table 5: Chemotherapy Drugs for Hodgkin Lymphoma

Table 6: Total Incident Cases of lymphoma in the 7MM (2018–2030)

Table 7: Type-specific Incident cases of Lymphoma in 7MM (2018–2030)

Table 8: Stage-Specific Incidence of Lymphoma in the 7MM (2018–2030)

Table 9: Chemotherapy Treated Lymphoma Patients in the 7MM (2018–2030)

Table 10: Frequency of Severe Toxicities in Lymphoma Patients in the 7MM (2018–2030)

Table 11: Total Incident cases of Lymphoma in the United States (2018–2030)

Table 12: Type-specific Incident cases of Lymphoma in the United States (2018–2030)

Table 13: Stage-Specific Incidence of Lymphoma in the United States (2018–2030)

Table 14: Chemotherapy Treated Lymphoma Patients in the United States (2018–2030)

Table 15: Frequency of Severe Toxicities in Lymphoma Patients in the United States (2018–2030)

Table 16: Total Incident cases of Lymphoma in Germany (2018–2030)

Table 17: Type-specific Incident cases of Lymphoma in Germany (2018–2030)

Table 18: Stage-Specific Incidence of Lymphoma in Germany (2018–2030)

Table 19: Chemotherapy Treated Lymphoma Patients in Germany (2018–2030)

Table 20: Frequency of Severe Toxicities in Lymphoma Patients in Germany (2018–2030)

Table 21: Total Incident cases of Lymphoma in France (2018–2030)

Table 22: Type-specific Incident cases of Lymphoma in France (2018–2030)

Table 23: Stage-Specific Incidence of Lymphoma in France (2018–2030)

Table 24: Chemotherapy Treated Lymphoma Patients in France (2018–2030)

Table 25: Frequency of Severe Toxicities in Lymphoma Patients in France (2018–2030)

Table 26: Total Incident cases of Lymphoma in Italy (2018–2030)

Table 27: Type-specific Incident cases of Lymphoma in Italy (2018–2030)

Table 28: Stage-Specific Incidence of Lymphoma in Italy (2018–2030)

Table 29: Chemotherapy Treated Lymphoma Patients in Italy (2018–2030)

Table 30: Frequency of Severe Toxicities in Lymphoma Patients in Italy (2018–2030)

Table 31: Total Incident cases of Lymphoma in Spain (2018–2030)

Table 32: Type-specific Incident cases of Lymphoma in Spain (2018–2030)

Table 33: Stage-Specific Incidence of Lymphoma in Spain (2018–2030)

Table 34: Chemotherapy Treated Lymphoma Patients in Spain (2018–2030)

Table 35: Frequency of Severe Toxicities in Lymphoma Patients in Spain (2018–2030)

Table 36: Total Incident cases of Lymphoma in the United Kingdom (2018–2030)

Table 37: Type-specific Incident cases of Lymphoma in the United kingdom (2018–2030)

Table 38: Stage-Specific Incidence of Lymphoma in the United Kingdom (2018–2030)

Table 39: Chemotherapy Treated Lymphoma Patients in the United Kingdom (2018–2030)

Table 40: Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom (2018–2030)

Table 41: Total Incident cases of Lymphoma in Japan (2018–2030)

Table 42: Type-specific Incident cases of Lymphoma in Japan (2018–2030)

Table 43: Stage-Specific Incidence of Lymphoma in Japan (2018–2030)

Table 44: Chemotherapy Treated Lymphoma Patients in Japan (2018–2030)

Table 45: Frequency of Severe Toxicities in Lymphoma Patients in Japan (2018–2030)

Table 46: AB-205, Clinical Trial Description

Table 47: 7MM Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 48: 7MM Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 49: Total United States Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 50: The United States Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 51: Germany Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 52: Germany Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 53: France Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 54: France Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 55: Italy Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 56: Italy Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 57: Spain Market Size of severe toxicities in lymphoma, in USD Million (2018–2030)

Table 58: Spain Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 59: The United Kingdom Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)

Table 60: The United Kingdom Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

Table 61: Japan Market Size of severe toxicities in lymphoma, in USD Million (2018–2030)

Table 62: Japan Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)

List of Figures

Figure 1: Severe Toxicities in Lymphoma SWOT Analysis

Figure 2: Abnormal cells in Lymphoma

Figure 3: Potential toxicities due to lymphoma treatment

Figure 4: Common cancers after lymphoma treatment

Figure 5: CRS toxicities by organ system

Figure 6: Spirometry Test

Figure 7: Echocardiography

Figure 8: Global Heat Map of Lymphoma

Figure 9: Total Incident Cases of lymphoma in the 7MM (2018–2030)

Figure 10: Type-specific Incident cases of Lymphoma in 7MM (2018–2030)

Figure 11: Stage-Specific Incidence of Lymphoma in the 7MM (2018–2030)

Figure 12: Chemotherapy Treated Lymphoma Patients in the 7MM (2018–2030)

Figure 13: Frequency of Severe Toxicities in Lymphoma Patients in the 7MM (2018–2030)

Figure 14: Total Incident cases of Lymphoma in the United States (2018–2030)

Figure 15: Type-specific Incident cases of Lymphoma in the United States (2018–2030)

Figure 16: Stage-Specific Incidence of Lymphoma in the United States (2018–2030)

Figure 17: Chemotherapy Treated Lymphoma Patients in the United States (2018–2030)

Figure 18: Frequency of Severe Toxicities in Lymphoma Patients in the United States (2018–2030)

Figure 19: Total Incident cases of Lymphoma in Germany (2018–2030)

Figure 20: Type-specific Incident cases of Lymphoma in Germany (2018–2030)

Figure 21: Stage-Specific Incidence of Lymphoma in Germany (2018–2030)

Figure 22: Chemotherapy Treated Lymphoma Patients in Germany (2018–2030)

Figure 23: Frequency of Severe Toxicities in Lymphoma Patients in Germany (2018–2030)

Figure 24: Total Incident cases of Lymphoma in France (2018–2030)

Figure 25: Type-specific Incident cases of Lymphoma in France (2018–2030)

Figure 26: Stage-Specific Incidence of Lymphoma in France (2018–2030)

Figure 27: Chemotherapy Treated Lymphoma Patients in France (2018–2030)

Figure 28: Frequency of Severe Toxicities in Lymphoma Patients in France (2018–2030)

Figure 29: Total Incident cases of Lymphoma in Italy (2018–2030)

Figure 30: Type-specific Incident cases of Lymphoma in Italy (2018–2030)

Figure 31: Stage-Specific Incidence of Lymphoma in Italy (2018–2030)

Figure 32: Chemotherapy Treated Lymphoma Patients in Italy (2018–2030)

Figure 33: Frequency of Severe Toxicities in Lymphoma Patients in Italy (2018–2030)

Figure 34: Total Incident cases of Lymphoma in Spain (2018–2030)

Figure 35: Type-specific Incident cases of Lymphoma in Spain (2018–2030)

Figure 36: Stage-Specific Incidence of Lymphoma in Spain (2018–2030)

Figure 37: Chemotherapy Treated Lymphoma Patients in Spain (2018–2030)

Figure 38: Frequency of Severe Toxicities in Lymphoma Patients in Spain (2018–2030)

Figure 39: Total Incident cases of Lymphoma in the United Kingdom (2018–2030)

Figure 40: Type-specific Incident cases of Lymphoma in the United kingdom (2018–2030)

Figure 41: Stage-Specific Incidence of Lymphoma in the United Kingdom (2018–2030)

Figure 42: Chemotherapy Treated Lymphoma Patients in the United Kingdom (2018–2030)

Figure 43: Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom (2018–2030)

Figure 44: Total Incident cases of Lymphoma in Japan (2018–2030)

Figure 45: Type-specific Incident cases of Lymphoma in Japan (2018–2030)

Figure 46: Stage-Specific Incidence of Lymphoma in Japan (2018–2030)

Figure 47: Chemotherapy Treated Lymphoma Patients in Japan (2018–2030)

Figure 48: Frequency of Severe Toxicities in Lymphoma Patients in Japan (2018–2030)

Angiocrine Bioscience

  • Tags:
  • Severe Toxicities in Lymphoma marke...
  • Severe Toxicities in Lymphoma mark...
  • Severe Toxicities in Lymphoma Comp...
  • Severe Toxicities in Lymphoma mark...
  • Severe Toxicities in Lymphoma mark...
  • Severe Toxicities in Lymphoma mark...
  • Severe Toxicities in Lymphoma pipe...
  • Severe Toxicities in Lymphoma trea...
  • Severe Toxicities in Lymphoma drug...
  • Severe Toxicities in Lymphoma sale...
  • Severe Toxicities in Lymphoma mark...
  • Severe Toxicities in Lymphoma dise...
  • Severe Toxicities in Lymphoma epid...
  • Severe Toxicities in Lymphoma

Forward to Friend

Need A Quote